SCHEMBL1973549

SCHEMBL1973549

COC(=O)c1sccc1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.57
HPGD P15428 3/20 0.57
ALDH1A1 P00352 3/20 0.57
GLA P06280 1/20 0.57
GAA P10253 1/20 0.57
MAPK1 P28482 1/20 0.57
KMT2A Q03164 4/20 0.53
NPC1 O15118 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
MEN1 O00255 2/20 0.50
CYP1A2 P05177 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
LMNA P02545 2/20 0.48
MAPK10 P53779 2/20 0.48
MAPK8 P45983 1/20 0.48
MAPK9 P45984 1/20 0.48
NPSR1 Q6W5P4 2/20 0.46
MAPT P10636 1/20 0.46
POLB P06746 1/20 0.45
PKM P14618 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL70575 0.88 KMT2A (0.56) KDM4EHPGDALDH1A1MAPK1KMT2A
SCHEMBL1974763 0.85 KDM4E (0.51) KDM4EHPGDALDH1A1GLAGAA
SCHEMBL2654173 0.85 KMT2A (0.54) KDM4EHPGDALDH1A1MAPK1KMT2A
SCHEMBL698811 0.84 ALDH1A1 (0.51) KDM4EHPGDALDH1A1GLAGAA
SCHEMBL25304281 0.83 KMT2A (0.51) KDM4EHPGDALDH1A1GAAMAPK1
SCHEMBL3977005 0.83 ALDH1A1 (0.55) KDM4EHPGDALDH1A1GAAMAPK1
SCHEMBL28412622 0.81 KMT2A (0.50) KDM4EHPGDALDH1A1MAPK1KMT2A
SCHEMBL30002631 0.81 ALDH1A1 (0.49) KDM4EHPGDALDH1A1GLAGAA
SCHEMBL5239795 0.80 MAPK8 (0.51) KDM4EHPGDALDH1A1GLAGAA
SCHEMBL25261430 0.80 HPGD (0.49) KDM4EHPGDALDH1A1GAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115821578-A Antistatic wear-resistant carpet and preparation method thereof 杨晓光 2023-03-21 CN claimed
US-20250066290-A1 DHODH INHIBITORS CONTAINING A CARBOXYLIC ACID BIOISOSTERE IMMUNIC AG (DE) 2025-02-27 US disclosed
EP-4452929-A1 DHODH INHIBITORS CONTAINING A CARBOXYLIC ACID BIOISOSTERE Immunic AG (DE) 2024-10-30 EP disclosed
CN-118382610-A DHODH inhibitors containing carboxylic acid bioisosteres 埃慕尼克股份公司 2024-07-23 CN disclosed
US-20240199535-A1 DEUTERATED DHODH INHIBITORS IMMUNIC AG (DE) 2024-06-20 US disclosed
EP-4320100-A1 DEUTERATED DHODH INHIBITORS Immunic AG (DE) 2024-02-14 EP disclosed
CN-117321035-A Deuterated DHODH inhibitors 埃慕尼克股份公司 2023-12-29 CN disclosed
WO-2023118576-A1 DHODH INHIBITORS CONTAINING A CARBOXYLIC ACID BIOISOSTERE IMMUNIC AG (DE) 2023-06-29 WO disclosed
WO-2023118576-A1 DHODH INHIBITORS CONTAINING A CARBOXYLIC ACID BIOISOSTERE IMMUNIC AG (DE) 2023-06-29 WO disclosed
CN-115821578-A Antistatic wear-resistant carpet and preparation method thereof 杨晓光 2023-03-21 CN disclosed
US-20140221422-A1 NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. (US) 2014-08-07 US disclosed
US-8703795-B2 Thienopyridine compounds, and methods of use thereof FIBROGEN, INC. (US) 2014-04-22 US disclosed
EP-1866318-B1 THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN INC (US) 2011-06-22 EP disclosed
US-7511070-B2 Compounds and therapies for the prevention of vascular and non-vascular pathologies PONIARD PHARMACEUTICALS, INC. (US) 2009-03-31 US disclosed
EP-1866318-A2 THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. (US) 2007-12-19 EP disclosed
WO-2006094292-A2 THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. (US) 2006-09-08 WO disclosed
US-20060199836-A1 Novel thienopyridine compounds, and methods of use thereof FIBROGEN, INC. 2006-09-07 US disclosed
EP-0267794-B1 PROCESS FOR PREPARING POLYOLEFINS Nippon Petrochemicals Co., Ltd. (JP) 1993-05-05 EP disclosed
EP-0267794-A2 Process for preparing polyolefins Nippon Petrochemicals Co., Ltd. (JP) 1988-05-18 EP disclosed
US-4525555-A TITANIUM COMPOUND SUPPORTED ON SOLID REACTION PRODUCT OF MAGNESIUM HALIDE, SILOXANES, ORGANIC COMPOUNDS NIPPON OIL COMPANY, LIMITED (JP) 1985-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221422-A1 NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN2 KDM4E 679/4885HPGD 21/4885ALDH1A1 488/4885
US-20060199836-A1 Novel thienopyridine compounds, and methods of use thereof HIF1AN, HIF1A, EGLN2 KDM4E 679/4885HPGD 21/4885ALDH1A1 488/4885
US-20250066290-A1 DHODH INHIBITORS CONTAINING A CARBOXYLIC ACID BIOISOSTERE DHODH, DBH, DOHH KDM4E 2435/4885HPGD 66/4885ALDH1A1 35/4885
US-20240199535-A1 DEUTERATED DHODH INHIBITORS DHODH, DBH, QDPR KDM4E 1617/4885HPGD 34/4885ALDH1A1 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.